Share-based Payment Arrangement, Expense of eFFECTOR Therapeutics, Inc. from 30 Jun 2020 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
eFFECTOR Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 31 Mar 2024.
  • eFFECTOR Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $1,000,000, a 17% decline year-over-year.
  • eFFECTOR Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $4,400,000, a 19% decline year-over-year.
  • eFFECTOR Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4,600,000, a 8% decline from 2022.
  • eFFECTOR Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,000,000, a 400% increase from 2021.
  • eFFECTOR Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1,000,000, a 100% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

eFFECTOR Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $4,400,000 $1,000,000 -$200,000 -17% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $4,600,000 $1,100,000 -$300,000 -21% 01 Oct 2023 31 Dec 2023 10-K 26 Mar 2024 2023 Q4
Q3 2023 $4,900,000 $1,100,000 -$500,000 -31% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $5,400,000 $1,200,000 $0 0% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $5,400,000 $1,200,000 +$400,000 +50% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $5,000,000 $1,400,000 +$1,000,000 +250% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 Q4
Q3 2022 $4,000,000 $1,600,000 +$1,400,000 +700% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $2,600,000 $1,200,000 +$1,000,000 +500% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $1,600,000 $800,000 +$600,000 +300% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $1,000,000 $400,000 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023 2022 Q4
Q3 2021 $200,000 $0 0% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $200,000 +$100,000 +100% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $200,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $200,000 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $100,000 01 Apr 2020 30 Jun 2020 8-K 31 Aug 2021

eFFECTOR Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $4,600,000 -$400,000 -8% 01 Jan 2023 31 Dec 2023 10-K 26 Mar 2024 2023 FY
2022 $5,000,000 +$4,000,000 +400% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $1,000,000 +$500,000 +100% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
2020 $500,000 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.